Open Access. Powered by Scholars. Published by Universities.®
Articles 1 - 1 of 1
Full-Text Articles in Medicine and Health Sciences
Mitochondrial Targeted Antioxidants, Mitoquinone And Skq1, Not Vitamin C, Mitigate Doxorubicin-Induced Damage In H9c2 Myoblast: Pretreatment Vs. Co-Treatment, Brian Sacks, Halil Onal, Rose Martorana, Amogh Sehgal, Amanda Harvey, Catherine Wastella, Hafsa Ahmad, Erin Ross, Adona Pjetergjoka, Sachin Prasad, Robert J. Barsotti, Lindon H. Young, Qian Chen
Mitochondrial Targeted Antioxidants, Mitoquinone And Skq1, Not Vitamin C, Mitigate Doxorubicin-Induced Damage In H9c2 Myoblast: Pretreatment Vs. Co-Treatment, Brian Sacks, Halil Onal, Rose Martorana, Amogh Sehgal, Amanda Harvey, Catherine Wastella, Hafsa Ahmad, Erin Ross, Adona Pjetergjoka, Sachin Prasad, Robert J. Barsotti, Lindon H. Young, Qian Chen
PCOM Scholarly Papers
BACKGROUND: Preconditioning of the heart ameliorates doxorubicin (Dox)-induced cardiotoxicity. We tested whether pretreating cardiomyocytes by mitochondrial-targeted antioxidants, mitoquinone (MitoQ) or SKQ1, would provide better protection against Dox than co-treatment.
METHODS: We investigated the dose-response relationship of MitoQ, SKQ1, and vitamin C on Dox-induced damage on H9c2 cardiomyoblasts when drugs were given concurrently with Dox (e.g., co-treatment) or 24 h prior to Dox (e.g., pretreatment). Moreover, their effects on intracellular and mitochondrial oxidative stress were evaluated by 2,7-dichlorofluorescin diacetate and MitoSOX, respectively.
RESULTS: Dox (0.5-50 μM, n = 6) dose-dependently reduced cell viability. By contrast, co-treatment of MitoQ (0.05-10 μM, n …